PL368319A1 - Pharmaceutical compositions comprising polysaccharide conjugates for inhibiting the metastsis or preventing the recurrence ofmaligant tumor - Google Patents
Pharmaceutical compositions comprising polysaccharide conjugates for inhibiting the metastsis or preventing the recurrence ofmaligant tumorInfo
- Publication number
- PL368319A1 PL368319A1 PL02368319A PL36831902A PL368319A1 PL 368319 A1 PL368319 A1 PL 368319A1 PL 02368319 A PL02368319 A PL 02368319A PL 36831902 A PL36831902 A PL 36831902A PL 368319 A1 PL368319 A1 PL 368319A1
- Authority
- PL
- Poland
- Prior art keywords
- ofmaligant
- metastsis
- recurrence
- tumor
- inhibiting
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001249717 | 2001-08-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL368319A1 true PL368319A1 (en) | 2005-03-21 |
Family
ID=19078678
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL02368319A PL368319A1 (en) | 2001-08-21 | 2002-08-16 | Pharmaceutical compositions comprising polysaccharide conjugates for inhibiting the metastsis or preventing the recurrence ofmaligant tumor |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP1418947A1 (xx) |
| KR (1) | KR20040027972A (xx) |
| CN (1) | CN100372570C (xx) |
| AR (1) | AR035137A1 (xx) |
| AU (1) | AU2002328093B2 (xx) |
| BR (1) | BR0212036A (xx) |
| CA (1) | CA2457056C (xx) |
| HU (1) | HUP0401351A3 (xx) |
| IL (1) | IL160148A0 (xx) |
| MX (1) | MXPA04001599A (xx) |
| NO (1) | NO20041194L (xx) |
| NZ (1) | NZ530947A (xx) |
| PL (1) | PL368319A1 (xx) |
| RU (1) | RU2275913C2 (xx) |
| TW (1) | TWI313609B (xx) |
| UA (1) | UA75450C2 (xx) |
| WO (1) | WO2003015826A1 (xx) |
| ZA (1) | ZA200400917B (xx) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200306314A (en) * | 2002-04-16 | 2003-11-16 | Tanabe Seiyaku Co | Liquid preparation comprising camptothecin derivative and pharmaceutical composition producible by lyophilizing the preparation |
| FR2914305B1 (fr) * | 2007-03-29 | 2009-07-03 | Proteins & Peptides Man | Dextran fonctionnalise par des amino-acides hydrophobes. |
| DK2313487T3 (en) | 2008-07-16 | 2018-06-18 | Childrens Medical Center | ORGANIZING DEVICE WITH MICRO-CHANNELS AND METHODS OF APPLICATION |
| WO2012166903A1 (en) | 2011-06-02 | 2012-12-06 | President And Fellows Of Harvard College | Methods and uses for ex vivo tissue culture systems |
| PL221351B1 (pl) | 2012-03-14 | 2016-03-31 | Politechnika Warszawska | Sposób otrzymywania nanocząstek polisacharydowych |
| DK2907824T3 (en) | 2012-10-11 | 2018-07-23 | Daiichi Sankyo Co Ltd | ANTIBODY-drug conjugate |
| ES2782248T3 (es) | 2012-10-19 | 2020-09-11 | Daiichi Sankyo Co Ltd | Conjugado de anticuerpo y fármaco producido por la unión a través de un enlazador que tiene estructura hidrófila |
| DK3466976T3 (da) | 2014-01-31 | 2021-12-13 | Daiichi Sankyo Co Ltd | Anti-her2-antistof-lægemiddelkonjugat |
| EP3292146A1 (en) | 2015-05-04 | 2018-03-14 | Pfizer Inc | Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof |
| AU2016286898B2 (en) | 2015-06-29 | 2022-12-08 | Daiichi Sankyo Company, Limited | Method for selectively manufacturing antibody-drug conjugate |
| WO2018110515A1 (ja) | 2016-12-12 | 2018-06-21 | 第一三共株式会社 | 抗体－薬物コンジュゲートと免疫チェックポイント阻害剤の組み合わせ |
| KR102537651B1 (ko) | 2017-01-17 | 2023-05-26 | 다이이찌 산쿄 가부시키가이샤 | 항 gpr20 항체 및 항 gpr20 항체-약물 콘쥬게이트 |
| TWI794230B (zh) | 2017-05-15 | 2023-03-01 | 日商第一三共股份有限公司 | 抗ｃｄｈ６抗體及抗ｃｄｈ６抗體-藥物結合物、以及其製造方法 |
| CA3073924C (en) | 2017-08-31 | 2023-10-17 | Daiichi Sankyo Company, Limited | Improved method for producing antibody-drug conjugate |
| BR112020003466B1 (pt) | 2017-08-31 | 2023-12-12 | Daiichi Sankyo Company, Limited | Métodos de produção de composto, e, composto |
| JP2021524740A (ja) | 2018-05-18 | 2021-09-16 | グリコトープ ゲーエムベーハー | 抗ｍｕｃ１抗体 |
| CN109481691A (zh) * | 2018-11-20 | 2019-03-19 | 珠海天香苑生物科技发展股份有限公司 | 吉西他滨-羧甲基多糖共轭物、制备方法及其用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2134348C (en) * | 1993-02-26 | 2007-01-02 | Hideo Nogusa | Polysaccharide derivatives and drug carriers |
| SG50747A1 (en) * | 1995-08-02 | 1998-07-20 | Tanabe Seiyaku Co | Comptothecin derivatives |
| CA2192725C (en) * | 1995-12-28 | 2004-04-20 | Kenji Tsujihara | Camptothecin derivatives |
| EP0895784B1 (en) * | 1996-04-15 | 2005-11-23 | Asahi Kasei Kabushiki Kaisha | Drug complexes comprising taxane compounds or steroids |
| TW527183B (en) * | 1996-06-06 | 2003-04-11 | Daiichi Seiyaku Co | Drug complex |
| CN1058038C (zh) * | 1996-12-31 | 2000-11-01 | 中国科学院感光化学研究所 | 低收缩性光固化涂层材料及其制法和用途 |
| CN1250293C (zh) * | 1998-05-22 | 2006-04-12 | 第一制药株式会社 | 药物复合物 |
-
2002
- 2002-08-14 TW TW091118260A patent/TWI313609B/zh not_active IP Right Cessation
- 2002-08-15 AR ARP020103077A patent/AR035137A1/es unknown
- 2002-08-16 NZ NZ530947A patent/NZ530947A/en not_active IP Right Cessation
- 2002-08-16 EP EP02762786A patent/EP1418947A1/en not_active Withdrawn
- 2002-08-16 AU AU2002328093A patent/AU2002328093B2/en not_active Ceased
- 2002-08-16 CN CNB028163176A patent/CN100372570C/zh not_active Expired - Fee Related
- 2002-08-16 KR KR10-2004-7002566A patent/KR20040027972A/ko not_active Application Discontinuation
- 2002-08-16 CA CA002457056A patent/CA2457056C/en not_active Expired - Fee Related
- 2002-08-16 BR BR0212036-4A patent/BR0212036A/pt not_active IP Right Cessation
- 2002-08-16 WO PCT/JP2002/008309 patent/WO2003015826A1/en active IP Right Grant
- 2002-08-16 HU HU0401351A patent/HUP0401351A3/hu unknown
- 2002-08-16 PL PL02368319A patent/PL368319A1/xx not_active Application Discontinuation
- 2002-08-16 RU RU2004108141/15A patent/RU2275913C2/ru not_active IP Right Cessation
- 2002-08-16 MX MXPA04001599A patent/MXPA04001599A/es unknown
- 2002-08-16 UA UA2004032071A patent/UA75450C2/uk unknown
- 2002-08-16 IL IL16014802A patent/IL160148A0/xx unknown
-
2004
- 2004-02-04 ZA ZA200400917A patent/ZA200400917B/en unknown
- 2004-03-19 NO NO20041194A patent/NO20041194L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2457056C (en) | 2008-07-22 |
| BR0212036A (pt) | 2004-08-17 |
| ZA200400917B (en) | 2004-08-25 |
| CN1545423A (zh) | 2004-11-10 |
| NO20041194L (no) | 2004-03-19 |
| IL160148A0 (en) | 2004-07-25 |
| TWI313609B (en) | 2009-08-21 |
| KR20040027972A (ko) | 2004-04-01 |
| EP1418947A1 (en) | 2004-05-19 |
| WO2003015826A1 (en) | 2003-02-27 |
| HUP0401351A3 (en) | 2011-02-28 |
| RU2004108141A (ru) | 2005-04-20 |
| HUP0401351A2 (hu) | 2004-12-28 |
| CA2457056A1 (en) | 2003-02-27 |
| RU2275913C2 (ru) | 2006-05-10 |
| AU2002328093B2 (en) | 2005-05-05 |
| UA75450C2 (en) | 2006-04-17 |
| CN100372570C (zh) | 2008-03-05 |
| MXPA04001599A (es) | 2004-07-08 |
| AR035137A1 (es) | 2004-04-14 |
| NZ530947A (en) | 2006-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200208163B (en) | Pharmaceutical compositions comprising fluvastatin. | |
| HUP0202513A2 (en) | Betha-carboline pharmaceutical compositions | |
| ZA200003998B (en) | Pharmaceutical compositions. | |
| HK1072200A1 (en) | Pro-micelle pharmaceutical compositions | |
| GB0028088D0 (en) | Pharmaceutical compositions | |
| GB0001662D0 (en) | Pharmaceutical compositions | |
| GB0111597D0 (en) | Pharmaceutical compositions | |
| IL145290A0 (en) | Pharmaceutical compositions comprising complexes | |
| HUP0401351A3 (en) | Pharmaceutical compositions comprising polysaccharide conjugates for inhibiting the metastsis or preventing the recurrence ofmaligant tumor | |
| HK1048271A1 (en) | Pharmaceutical composition for inhibiting retinoidskin damage. | |
| GB9923436D0 (en) | Pharmaceutical compositions | |
| ZA200210359B (en) | Pharmaceutical compositions. | |
| GB9904163D0 (en) | Pharmaceutical compositions | |
| MXPA03002105A (es) | Composiciones farmaceuticas. | |
| HK1068277A1 (en) | Pharmaceutical compositions comprising chelidonineor derivatives thereof | |
| GB9911017D0 (en) | Pharmaceutical compositions | |
| GB0104752D0 (en) | Pharmaceutical compositions | |
| GB9904911D0 (en) | Pharmaceutical compositions | |
| GB2382302B (en) | Pharmaceutical compositions | |
| GB9902651D0 (en) | Pharmaceutical compositions | |
| HUP0200253A3 (en) | Pharmaceutical compositions for combination therapy | |
| ZA200110500B (en) | Pharmaceutical composition. | |
| MXPA03007318A (es) | Composicion farmaceutica. | |
| ZA200110501B (en) | Pharmaceutical composition. | |
| GB0126732D0 (en) | Pharmaceutical compositions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| REFS | Decisions on refusal to grant patents (taken after the publication of the particulars of the applications) |